---
document_datetime: 2025-08-07 15:54:25
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/lysakare-epar-all-authorised-presentations_en.pdf
document_name: lysakare-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.7277653
conversion_datetime: 2025-12-30 20:23:12.694083
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| MA (EU) number   | (Invented) name   | Strength    | Pharmaceutical form   | Route of administration   | Immediate packaging   | Content (concentration)        | Pack size   |
|------------------|-------------------|-------------|-----------------------|---------------------------|-----------------------|--------------------------------|-------------|
| EU/1/19/1381/001 | LysaKare          | 25 g / 25 g | Solution for infusion | Intravenous use           | bag (PP)              | 1 000 mL (25 mg/mL + 25 mg/mL) | 1 bag       |